Prevents pregnancy. ANDA 91634, held by Glenmark Pharms Ltd. Ethinyl Estradiol; Norethindrone.
As of Nov 16, 2026, ANDA 91634 (Alyacen 1/35), held by Glenmark Pharms Ltd, was first approved by FDA on Jan 19, 2012, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE ALYACEN 7/7/7 and ALYACEN 1/35 Tabletsare indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the NORPLANT System depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 19, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Alyacen 1/350.035MG;1MG · tablet;oral-28 | Ethinyl Estradiol; Norethindrone | Rx |
| Jul 6, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 6, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 16, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 29, 2013 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 31, 2012 | Supplement 1Labeling | Approved | None posted |
| Jan 19, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters